GlassScriptPhysician profile
Junfang Jiao
NPI 1033455381
$19,807.58
in general payments reported to CMS, 2019-2025
41 companies · $1,684 in 2025
The $1,684 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,639 · 2020: $1,533 · 2021: $1,979 · 2022: $2,632 · 2023: $7,050 · 2024: $2,291 · 2025: $1,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,365 · Consulting Fee: $4,125 · Travel and Lodging: $712 · Education: $473 · Honoraria: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,365.29 |
| Consulting Fee | $4,125.00 |
| Travel and Lodging | $712.00 |
| Education | $472.81 |
| Honoraria | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $4,837.00 | 2023 | Xolair |
| Astrazeneca Pharmaceuticals LP | $2,634.53 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,057.85 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,680.59 | 2019-2025 | Dupixent |
| Pfizer INC. | $1,183.37 | 2019-2025 | |
| Genzyme Corporation | $1,084.84 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $772.73 | 2020-2025 | Hyqvia, Cuvitru, Eohilia |
| Biocryst US Sales Co., LLC | $735.46 | 2021-2025 | Orladeyo |
| Csl Behring | $692.24 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Abbvie INC. | $624.95 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $602.73 | 2021-2024 | |
| Genentech USA, INC. | $453.89 | 2019-2025 | Xolair |
| Amgen INC. | $245.73 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $237.35 | 2021-2023 | |
| Pharming Healthcare, INC. | $187.60 | 2019-2023 | Ruconest |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junfang Jiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.